A gene-matched Alzheimer’s drug that slows early symptoms is now approved for use. Patients will need genetic screening, fortnightly infusions, and regular brain scans to stay on treatment.

Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new ...

Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

A groundbreaking study by Geneva University Hospitals (HUG) and the University of Geneva (UNIGE) has found that adults with attention deficit disorder (ADHD), with or without hyperactivity, exhibit ...

Daily doses of obicetrapib over 52 weeks led to significant reductions in plasma p-tau217 and other Alzheimer’s disease ...

Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's ...

This excerpt from the new book Born to Walk will give you plenty of reasons to take your daily strolls seriously.

ADHD diagnosis currently relies on behavioral tests and patient interviews – could biomarkers offer a more accurate and ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

Older women with a history of TBI show significantly reduced volume in memory-related brain regions compared with uninjured peers — a pattern not observed in men, new research shows.